The role of solithromycin in the management of bacterial community-acquired pneumonia.
(2016) Expert Review of Anti-infective Therapy — Vol. 14, n° 3, p. 311-324 (2016)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- The fluoroketolide solithromycin is 2-fold more potent in vitro than telithromycin against pneumococci (including macrolide-resistant strains) and Haemophilus influenzae and very active on pathogens causing atypical pneumonia. In contrast, it is a 30-fold less potent inhibitor of nicotinic receptors incriminated in telithromycin toxicity. In Phase II/III trials, oral solithromycin once-daily (800 mg on day 1; 400 mg on days 2-5) proved effective and safe when compared to respiratory fluoroquinolones for the treatment of community-acquired bacterial pneumonia (CABP). A Phase III intravenous trial vs. moxifloxacin has been recently completed for the same indication. Solithromycin may restore interest in ketolides as a first-line therapy for CAPB. Solithromycin safety should nevertheless be confirmed in larger populations allowing for detection of rare adverse events.
- Affiliations
Citations
Van Bambeke, F., & Tulkens, P. M. (2016). The role of solithromycin in the management of bacterial community-acquired pneumonia. Expert Review of Anti-infective Therapy, 14(3), 311-324. https://doi.org/10.1586/14787210.2016.1138857 (Original work published 2016)